Emerging Drug Developer: Juvaris BioTherapeutics

Juvaris BioTherapeutics

Kleiner Perkins was so impressed by the research work underway at Juvaris BioTherapeutics, the venture group ended up investing $12 million last year in the company's Series A round. And last March, Kleiner Perkins helped engineer the arrival of Grant Pickering to run the vaccine company with an eye to taking Juvaris to proof-of-concept data on a slate of vaccine development programs. 

Just weeks ago Juvaris launched its first clinical study, a Phase I trial of a vaccine adjuvant--JVRS-100--combined with a commercially available vaccine for seasonal influenza. And now the small biotech has a full slate of programs nearing the clinic. By the end of this year, the developer plans to have its first look at efficacy data in humans and a new round of venture capital in the bank. Article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.